Artivion (AORT) Stock Forecast & Price Target

Artivion is positioned for a positive fundamental reacceleration because its early-2025 AMDS launch and the expected 1Q27 NEXUS launch add two major growth engines with large addressable markets, while the company also has additional PMAs and Arcevo in development. The recent guidance reset appears temporary rather than structural, driven by a resolved stent graft supplier issue, AMDS purchasing friction tied to the $100,000 starter set and IRB requirements, and softer Middle Eastern sales. With revenue already supported by On-X acceleration, roughly 120 of 800 acute Type A dissection centers penetrated, and EBITDA margins rising from 13.3% to 20.3% from 2022 to 2025, the operating leverage story remains compelling.

Artivion is exposed to a fragile growth mix, with 49% of 2024 revenue coming from outside North America and management already flagging weaker OUS stent graft sales from the Middle East and supplier issues that were pushed into 2026. Its reliance on tissue preservation services adds another structural risk, since supply constraints, regulatory changes, and reputational or disease-transmission concerns can directly disrupt a significant source of revenue. On top of that, quality and regulatory overhangs—including EU MDR reclassification risk, possible FDA Class III treatment for SGPV, and increasing scrutiny of EtO sterilization—could pressure approvals, recalls, and margins, supporting a bearish outlook.